In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural fragment Kisspeptin-10 | Natural peptide Oxytocin | |
|---|---|---|---|
| Identity | |||
| Kind | Natural fragment | Natural peptide | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 1,457 (plus 233 on natural levels, listed separately) | 3,492 (plus 1,148 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 31 (0 in people) | 157 (152 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 17 · 3 active1 more mentions it but does not test it | 690 · 65 active238 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Kisspeptin-10 | Oxytocin |
|---|---|---|
| Cognition and memoryNervous system and cognition | 11 | 41440311 |
| Brain and neuronal activityEndocrine and hormones |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Pitocin says: “Antepartum: medically indicated induction of labor, stimulation or reinforcement of labor, adjunctive therapy in incomplete or inevitable abortion” No central EU authorisation (EMA).
55 |
38437437 |
| Anxiety and moodMental health and mood | 22 | 34132417 |
|---|
| Sex hormones and fertilityReproductive and sexual health | 60971423115 | 150328632 |
|---|
| Receptor activity and mechanismRespiratory | 24214218910 | 28960801472 |
|---|
| Adverse eventsWhole body | 651 | 1261233 |
|---|
| PainNervous system and cognition | 33 | 1098524 |
|---|
| Appetite and food intakeNervous system and cognition | 37307 | 946727 |
|---|
| PharmacokineticsPharmacology | 651 | 9168203 |
|---|
| Stress hormonesEndocrine and hormones | 33 | 7560123 |
|---|
| Sexual functionReproductive and sexual health | 1111 | 7647245 |
|---|
| Heart functionCardiovascular | 21129 | 76353110 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Kisspeptin-10 is the same as Kisspeptin-54 (metastin) residues 45 to 54, with 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 17 trials, ranked by phase, then posted results and enrollment: 3 completed · source ClinicalTrials.gov (opens in a new tab)
Ghulam Nabi30 participants26 Jun 2014 to 5 Mar 2015
Reproductive Physiological Phenomena
Quaid-e-Azam University15 participants8 Aug 2014 to 5 Mar 2015
Sterility, Reproductive
Quaid-e-Azam University14 participants29 Oct 2013 to 10 Jan 2014
Kisspeptin Action on Insulin in Healthy Normal Men · Kisspeptin Action on Insulin in Obese Diabetic Men
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 690 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
University of Alabama at Birmingham1,798 participantsNov 2008 to Jun 2010
Uterine Atony · Postpartum Hemorrhage
Northwestern University1,003 participants28 Sept 2015 to 28 Sept 2020
Dystocia
University of Zimbabwe506 participants8 Apr 2018 to 30 Jun 2019
Post Partum Hemorrhage
238 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Kisspeptin-10 | Oxytocin |
|---|---|---|
| Sex hormones and fertilityEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | No comparable result 14 randomized-trial results measure it in another way or another unit. | 14.4% Mean percent change testosterone Dose studied: 24 IUn = 452020 |
| Receptor activity and mechanismEndocrine and hormonesCompared as: value in the arm that got the peptide, in proteins | No comparable result 1 randomized-trial result measure it in another way or another unit. | 198 proteins Differentially expressed proteins Dose studied: 24 IUsingle dosen = 192026 |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in effect size | No randomized trial result 6 results from other study designs. | −1.12 effect size Effect size Dose studied: 48 IU/day6 weeksn = 1032020 |
| Appetite and food intakeGastrointestinalCompared as: difference from placebo, in kcal | No randomized trial result 37 results from other study designs. | −152 kcal Difference in caloric intake Dose studied: 24 IU four times daily8 weeksn = 612024 |
| Body weightMetabolic and weightCompared as: difference from placebo, in g | No randomized trial result 7 results from other study designs. | 196 g Difference in total fat Dose studied: 24 IU four times daily8 weeksn = 612024 |
| Energy expenditure and thermogenesisMetabolic and weightCompared as: difference from placebo, in kcal/day | No randomized trial result 5 results from other study designs. | −64 kcal/day Difference in resting energy expenditure Dose studied: 24 IU four times daily8 weeksn = 612024 |
| Liver fat and liver functionLiverCompared as: difference from placebo, in proportion | No randomized trial result 3 results from other study designs. | −0.01 proportion Difference in liver fat fraction Dose studied: 24 IU four times daily8 weeksn = 612024 |
| Brain and neuronal activityNervous system and cognitionCompared as: difference from placebo, in regions | No randomized trial result 5 results from other study designs. | 7 regions Regions with treatment effect Dose studied: 40 IUacute challengen = 472024 |
| Anxiety and moodMental health and moodCompared as: value in the arm that got the peptide, in % | No randomized trial result 2 results from other study designs. | −20% Score reduction · Shown as a change. The study reports a score reduction of this size. Placebo: −4% Dose studied: 20 IU twice daily in week 1, then 40 IU twice daily8 weeksn = 402013 |
| Sexual functionReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | No randomized trial result 11 results from other study designs. | 26% FSFI score change Placebo: 31% Dose studied: 32 IU8 weeksn = 302015 |
| Cognition and memoryMental health and moodCompared as: difference from placebo, in sd | No randomized trial result 1 result from other study designs. | 1.39 SD effect size n = 262017 |
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in mmol/l × min | No randomized trial result 30 results from other study designs. | 2240 mmol/L × min Glucose AUC Placebo: 2190 mmol/L × min Dose studied: 24 IUn = 252024 |
No comparable result
14 randomized-trial results measure it in another way or another unit.
14.4%
Mean percent change testosterone
Dose studied: 24 IUn = 452020
No comparable result
1 randomized-trial result measure it in another way or another unit.
198 proteins
Differentially expressed proteins
Dose studied: 24 IUsingle dosen = 192026
No randomized trial result
6 results from other study designs.
−1.12 effect size
Effect size
Dose studied: 48 IU/day6 weeksn = 1032020
No randomized trial result
37 results from other study designs.
−152 kcal
Difference in caloric intake
Dose studied: 24 IU four times daily8 weeksn = 612024
No randomized trial result
7 results from other study designs.
196 g
Difference in total fat
Dose studied: 24 IU four times daily8 weeksn = 612024
No randomized trial result
5 results from other study designs.
−64 kcal/day
Difference in resting energy expenditure
Dose studied: 24 IU four times daily8 weeksn = 612024
No randomized trial result
3 results from other study designs.
−0.01 proportion
Difference in liver fat fraction
Dose studied: 24 IU four times daily8 weeksn = 612024
No randomized trial result
5 results from other study designs.
7 regions
Regions with treatment effect
Dose studied: 40 IUacute challengen = 472024
No randomized trial result
2 results from other study designs.
−20%
Score reduction · Shown as a change. The study reports a score reduction of this size.
Placebo: −4%
Dose studied: 20 IU twice daily in week 1, then 40 IU twice daily8 weeksn = 402013
No randomized trial result
11 results from other study designs.
26%
FSFI score change
Placebo: 31%
Dose studied: 32 IU8 weeksn = 302015
No randomized trial result
1 result from other study designs.
1.39 SD
effect size
n = 262017
No randomized trial result
30 results from other study designs.
2240 mmol/L × min
Glucose AUC
Placebo: 2190 mmol/L × min
Dose studied: 24 IUn = 252024